financetom
Business
financetom
/
Business
/
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
May 25, 2025 9:02 PM

Novo Nordisk A/S ( NVO ) and Hims & Hers Health, Inc ( HIMS ). announced a long-term collaboration on Tuesday.

In March, Novo Nordisk ( NVO ) introduced NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy (semaglutide) for cash-paying patients.

Americans can now access NovoCare Pharmacy directly through the Hims & Hers platform. A bundled offering of all dose strengths of Wegovy and a Hims & Hers membership, which includes access to 24/7 care, ongoing clinical support, and nutrition guidance.

In March, Novo Nordisk ( NVO ) announced updates to the Wegovy savings program, allowing all eligible cash-paying patients to access Wegovy (semaglutide) injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their local pharmacy for a reduced cost of $499 per month.

Previously, the $499-per-month offer for Wegovy was only available via the recently launched NovoCare Pharmacy.

Also Read: Novo Nordisk Wins Legal Battle To Curb Unsafe Knockoff Versions Of Ozempic, Wegovy

On Tuesday, the company said that at a single, unified price starting at $599 per month, individuals may be prescribed Wegovy. The offering is available this week on the Hims & Hers platform.

The companies are also developing a roadmap that combines Novo Nordisk’s treatments with Hims & Hers’ ability to scale access to quality care, aiming to improve long-term outcomes for more people.

This new offering builds on Hims & Hers’ existing suite of weight loss solutions and provides self-pay patients with access to all dose strengths of Wegovy in a high-quality pen.

The platform will continue to offer access to other medications, oral kits, protein, nutrition kits, and clinically-backed care plans.

Earlier in April, Hims & Hers Health ( HIMS ) said it would offer Eli Lilly And Co's ( LLY ) Zepbound through its Telehealth platform.

In a blog post, Hims & Hers announced that it's expanding access to personalized weight loss care.

Hims & Hers said its GLP-1 offering generated over $225 million in revenue in 2024.

Price Action: HIMS stock is up 35.5% at $38.60 during the premarket session at the last check Tuesday.

Read Next:

UPS Delivers Mixed Bag: Q1 Supply Chain Weakness Offset By Strong Domestic And International Growth

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved